Presentations by Event

Presented at SCI-RSC Symposium on Antimicrobial Drug Discovery, November 2021

Discovery of ETX0462, a novel non-β-lactam PBP inhibitor to treat Gram-negative infections, including MDR Pseudomonas aeruginosa

Thomas Durand-Reville (SCI-RSC, 2021)

Program(s): etx0462

Presented at ECCMID, July 2021

In Vitro Activity of Sulbactam-Durlobactam against Recent Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

Sarah McLeod, Samir Moussa, Meredith Hackel and Alita Miller (ECCMID, 2021)

Program(s): durlobactam (etx2514)

Presented at World Microbe Forum, June 2021

The β-lactamase inhibitor ETX1317 restores the activity of cefpodoxime against recent (2017 2019), geographically diverse drug resistant Enterobacterales isolates

Sarah McLeod, Michael Huband, Jennifer Thompson, John Mueller and Alita Miller (Microbe, 2021)

Program(s): etx0282

ETX0462 is a Novel PBP Inhibitor with Potent Activity against Recent, Global, Gram-Negative Clinical Isolates

Sarah McLeod, Michael Huband, Jennifer Thompson, and Alita Miller (Microbe, 2021)

Program(s): etx0462

Sulbactam-Durlobactam MIC and Disk Diffusion Quality Control Ranges Using A CLSI M23-A4 Study Design

Sarah McLeod, Nicole Carter and Alita Miller (Microbe, 2021)

Program(s): durlobactam (etx2514)

Effect Of Susceptibility Testing Conditions On The In Vitro Antibacterial Activity Of Sulbactam-Durlobactam

Nicole Carter, Sarah McLeod and Alita Miller (Microbe, 2021)

Program(s): durlobactam (etx2514)

ETX0462 Inhibits Penicillin-binding Protein 3 of Pseudomonas aeruginosa and Escherichia coli

Adam B. Shapiro, Sarah M. McLeod, Samir H. Moussa and Alita A. Miller (Microbe, 2021)

Program(s): etx0462

The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Retains Potent Antibacterial Activity Across Isogenic Panels of Gram-negative Resistant Determinants

Sarah McLeod, Nicole Carter, Ramkumar Iyer, Samir Moussa and Alita Miller (Microbe, 2021)

Program(s): etx0462

The Discovery of the Novel Diazabicyclooctane (DBO) ETX0462: A Single Antibacterial Agent to Treat Gram-negative Infections, Including MDR Pseudomonas aeruginosa

Thomas Durand-Reville, Mark Sylvester, Janelle Comita, Frank Wu, Xiaoyun Wu, Jing Zhang, Jan Romero, Satenig Guler, Camilo Velez-Vega, Adam Shapiro, Nicole Carter, April Chen, Ramkumar Iyer, Samir Moussa, Sarah McLeod, Alita Miller, John O’Donnell and Ruben Tommasi (Microbe, 2021)

Program(s): etx0462

ETX0462, a Novel Non β-lactam PBP Inhibitor, Is Bactericidal Against Gram Negative Pathogens with a Low Propensity for Mutant Generation

Nicole Carter, Sarah McLeod, Samir Moussa and Alita Miller (Microbe, 2021)

Program(s): etx0462

Outer Membrane Permeability and Efflux Do Not Limit Antibacterial Activity of Sulbactam-Durlobactamin Acinetobacter baumannii

Nicole M. Carter, Samir H. Moussa, Sarah M. McLeod, Alita A. Miller and Ramkumar Iyer (Microbe, 2021)

Program(s): durlobactam (etx2514)

The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Has Potent Activity Against Biothreat Pathogens In Vitro and In Vivo

Ruben Tommasi, Henry Heine, George Drusano, Jason Cummings, Richard Slayden, Thomas Durand-Reville, John O’Donnell, and Alita Miller (Microbe, 2021)

Program(s): etx0462

ETX0462, A Novel Non-β-lactam PBP Inhibitor, Is Bactericidal Against Gram-Negative Pathogens

Thomas Durand-Reville (Microbe, 2021)

Program(s): etx0462

Evaluation of the Pharmacokinetics/pharmacodynamics (PK/PD) of the Novel Diazabicyclooctane (DBO) ETX0462 Against Pseudomonas aeruginosa Infections, Including MDR Strains

John O'Donnell, Angela Tanudra, April Chen, Dan Hines, Ruben Tommasi, Alita Miller, and Thomas Durand-Reville (Microbe, 2021)

Program(s): etx0462